The Medicare GLP-1 Bridge, Explained: Eligibility, Structure, and Sunset Date
The CMS demonstration program launched July 1, 2026, creating the first Medicare pathway for GLP-1 obesity treatment. Eligibility requirements, cost-sharing structure, the compounded medication exclusion, and the December 2027 sunset problem.
On July 1, 2026, the Centers for Medicare and Medicaid Services launched a demonstration program — informally called the "GLP-1 Bridge" — that provides Part D beneficiaries access to GLP-1 medications for obesity treatment through a temporary cost-sharing structure. The program runs through December 31, 2027, pending congressional action on permanent Medicare obesity drug coverage.
Why a Demonstration Program, Not Permanent Coverage
Medicare Part D has historically excluded weight loss medications from coverage under the "exclusion list" in 42 U.S.C. § 1395w-102(e)(2), which prohibits coverage of drugs used for "cosmetic purposes or hair growth." Congressional debate over removing GLP-1 medications from this exclusion has not yet produced a permanent legislative solution. The demonstration program allows CMS to provide coverage and collect cost-effectiveness data without requiring legislative change.
Eligibility Requirements
| Criterion | Requirement |
|---|---|
| Medicare enrollment | Part D coverage through any plan |
| BMI | ≥30 kg/m², or ≥27 kg/m² with qualifying comorbidity |
| Qualifying comorbidities (if BMI 27-30) | Type 2 diabetes, hypertension, dyslipidemia, sleep apnea, cardiovascular disease |
| Prior authorization | Required — prescriber must document BMI and indication |
| Covered medications | Semaglutide (Wegovy), tirzepatide (Zepbound) at FDA-approved obesity doses |
| Compounded medications | NOT covered under the demonstration program |
Cost-Sharing Structure
Under the demonstration, beneficiaries pay the standard Part D cost-sharing for non-preferred brand drugs through the initial coverage phase. After reaching the catastrophic threshold ($2,000 out-of-pocket under the Inflation Reduction Act cap), cost-sharing drops to zero. For beneficiaries with low-income subsidies, cost-sharing may be substantially lower from the first fill.
The program does not include donut hole gap coverage for these medications — beneficiaries in the initial coverage phase face the same cost structure as other brand-name drugs. This means access is significantly more affordable for low-income subsidy beneficiaries than for standard Part D enrollees.
The demonstration program expires December 31, 2027, unless extended by CMS or made permanent through legislation. Patients who begin GLP-1 treatment under the demonstration and have not achieved maintenance may face coverage loss at the sunset date. The long-term efficacy data on GLP-1 discontinuation (STEP-1 and SURMOUNT-4 extension trials) shows substantial weight regain after discontinuation — making the sunset date a clinical concern, not just an administrative one.
What This Does and Doesn't Change
The demonstration program creates a Medicare pathway that did not previously exist for obesity-indicated GLP-1 use. It does not affect coverage for GLP-1 medications prescribed for type 2 diabetes — those remain covered under existing Part D rules and are not part of this demonstration.
The compounded medication exclusion is specifically documented in CMS implementation guidance: "Compounded versions of semaglutide or tirzepatide are not covered under this demonstration regardless of whether they are produced by a 503A or 503B facility." This aligns with FDA's position on compounded drugs and Medicare coverage.
Looking for a GLP-1 provider?
Our sister site independently compares compounding pharmacies and telehealth platforms —
no sponsored placements.
Sources
- Centers for Medicare and Medicaid Services. "GLP-1 Receptor Agonist Obesity Treatment Demonstration Program." CMS Innovation Center. Published June 2026, effective July 1, 2026.
- 42 U.S.C. § 1395w-102(e)(2). Medicare Prescription Drug Benefit exclusions.
- Inflation Reduction Act (P.L. 117-169). Medicare drug cost-sharing cap provisions.
- SURMOUNT-4 investigators. "Tirzepatide Once Weekly After Discontinued Maintenance Therapy." NEJM. 2024.